PROSPECTUS SUPPLEMENT(to Prospectus dated December 2, 2024) 475,555 American Depositary Shares representing47,555,560 Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectusdated December 2, 2024 (the “Prospectus”), which forms a part of our Registration Statement on Form F-1(Registration No. 333-276774), with the information contained in our current report on Form 6-K, furnished to theSecurities and Exchange Commission on April 15, 2025 (the “April 15, 2025 Form 6-K”). Accordingly, we haveattached the April 15, 2025 Form 6-K to this prospectus supplement. This prospectus supplement updates and supplements the information in the Prospectus and is not complete without,and may not be delivered or utilized except in combination with, the Prospectus, including any amendments orsupplements thereto. This prospectus supplement should be read in conjunction with the Prospectus and if there isany inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on theinformation in this prospectus supplement. The ADSs are listed on The Nasdaq Capital Market (“Nasdaq”) under the symbol “KZIA.” On April 14, 2025, thelast reported sale price of the ADSs on Nasdaq was $0.7893 per ADS. Investing in our securities involves a high degree of risk. See “Risk Factors” beginning onpage 9 of the Prospectus and the “Risk Factors” in “Item 3. Key Information—D. RiskFactors” of our most recent Annual Report on Form 20-F, which is incorporated byreference in the Prospectus, as well as in any other recently filed reports and, if any, in anyapplicable prospectus supplement. Neither the Securities and Exchange Commission nor any state securities commission has approved ordisapproved of these securities or passed upon the adequacy or accuracy of the Prospectus or this prospectussupplement. Any representation to the contrary is a criminal offense. UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUERPURSUANT TO RULE 13a-16 OR 15d-16UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2025 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000(Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F☐Form 40-F☐ INFORMATION CONTAINED IN THIS FORM 6-K REPORT Kazia Therapeutics Limited (the “Company”) plans to change the ratio of its American Depositary Shares (“ADSs”)to Ordinary Shares from one (1) ADS representing one hundred (100) Ordinary Shares to one (1) ADS representingfive hundred (500) Ordinary Shares (the “ADS Ratio Change”). The ADS Ratio Change will have the same effect as a one-for-five reverse ADS split for our ADS holders. Therewill be no change to our underlying Ordinary Shares, and no Ordinary Shares will be issued or cancelled inconnection with the ADS Ratio Change. The effect of the ratio change on the ADS trading price on the NasdaqCapital Market is expected to take place at the opening of business on April 17, 2025. Following the ADS RatioChange, our ADSs will continue to be traded on the Nasdaq Capital Market under the ticker symbol “KZIA.” No fractional new ADSs will be issued in connection with the ADS Ratio Change. Instead, fractional entitlements tothe new ADSs will be aggregated and sold by the depositary bank, and the net cash proceeds from the sale of thefractional ADS entitlements (after deduction of fees, taxes, and expenses) will be distributed to the applicable ADSholders by the depositary bank. As a result of the ADS Ratio Change, the ADS price is expected to increase proportionally, although the Companycan give no assurance that the ADS price after the ADS Ratio Change will be equal to or greater than five times theADS price before the ADS Ratio Change. As of the date hereof, the Company has an aggregate of 6,798,129 ADSs issued and outstanding. Immediatelyfollowing the ADS Ratio Change, the Company will have an aggregate of 1,359,625 ADSs issued and outstanding. The Company’s Board of Directors approved the ADS Ratio Change with the objective of maintaining compliancewith the minimum bid price of $1.00 per share as outlined in the Nasdaq Listing Rules. The Company can give noassurance that this event will result in the Company maintaining compliance with Nasdaq’s minimum bid pricerequirement. The Company hereby incorporates by reference the information contained herein into the Company’s registrationstatements on Form F-3 (File No. 333-276091 and 333-281937). Forward-Looking Statements Certain statements in this Report on Form 6-K- that are forward-looking and not statements of historical fact areforward-looking statements, which can generally be identified a